Credit score: Pixabay/CC0 Public Area
A brand new evaluation from the COMPEL trial reveals that sufferers with EGFR-mutated (EGFRm) superior non-small cell lung most cancers (NSCLC) who skilled non-central nervous system (CNS) development on first-line osimertinib profit from persevering with osimertinib therapy together with platinum-based chemotherapy.
The research was offered on the Worldwide Affiliation for the Examine of Lung Most cancers 2025 World Convention on Lung Most cancers (WCLC).
The COMPEL research is a worldwide, randomized, double-blind trial, wherein grownup sufferers with non-CNS development on first-line osimertinib have been randomized 1:1 to obtain both osimertinib 80 mg as soon as each day or placebo as soon as each day together with platinum-pemetrexed chemotherapy (cisplatin 75 mg/m2 or carboplatin AUC5 + pemetrexed 500 mg/m2 each 3 weeks for 4 cycles), adopted by osimertinib 80 mg as soon as each day or placebo as soon as each day together with upkeep pemetrexed (500 mg/m2 each 3 weeks) till illness development or one other discontinuation criterion was met.
The research confirmed that persevering with osimertinib with the addition of platinum-pemetrexed chemotherapy was related to improved progression-free survival (PFS) in contrast with placebo plus chemotherapy (HR: 0.43; 95% CI: 0.27–0.70); median PFS was 8.4 months with osimertinib plus chemotherapy vs. 4.4 months with placebo plus chemotherapy. Median general survival (OS) was additionally longer with osimertinib plus chemotherapy (15.9 months) vs. placebo plus chemotherapy (9.8 months) (HR: 0.71; 95% CI: 0.42–1.23).
“These results indicate that resistance to first-line osimertinib may be heterogeneous, and some tumor cells remain sensitive to continued therapy,” stated lead investigator Dr. Giulia Pasello of the Veneto Institute of Oncology IOV-IRCCS in Italy. “This trial supports osimertinib as a backbone treatment strategy in this setting.”
Dr. Pasello reported that the protection and tolerability profile of the mix remedy was manageable and in line with the recognized security profiles of osimertinib and chemotherapy brokers. The findings additionally align with outcomes from the FLAURA2 research, which confirmed a profit for first-line osimertinib mixed with chemotherapy.
These outcomes might assist inform therapy choices and emphasize the significance of personalised methods for sufferers with EGFRm superior NSCLC following development on focused remedy, stated Dr. Pasello.
Offered by
Worldwide Affiliation for the Examine of Lung Most cancers
Quotation:
Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung most cancers (2025, September 6)
retrieved 6 September 2025
from https://medicalxpress.com/information/2025-09-osimertinib-chemotherapy-free-survival-egfr.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
